11 completed, 1 active not recruiting, 1 unknown. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 11, Active not recruiting 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Vascular Dementia: new trials by email Literature Review of Vascular Dementia trials Research Report on Vascular Dementia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia. Prospekta, Placebo - Vascular Dementia | Phase 3 | Completed | Materia Medica Holding | 406 | 2020-12-03 | 2024-10-28 |
| Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Butylphthalide soft capsule, Placebo soft capsule - Vascular Dementia | Phase 3 | Active not recruiting | Capital Medical University | 707 | 2019-10-29 | 2026-03-23 |
| The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule SaiLuoTong capsule, placebo - Vascular Dementia | Phase 3 | Completed | Shineway Pharmaceutical Co.,Ltd | 493 | 2019-04-10 | 2026-02-17 |
| Local Study of Akatinol Memantine in VaD in Russia Akatinol Memantine 20 mg, Akatinol Memantine 10 mg - Vascular Dementia | Phase 3 | Completed | Merz Pharmaceuticals GmbH | 130 | 2018-01-23 | 2022-07-22 |
| The Healthy Patterns Sleep Study Attention-Control Condition, Timed Activity Intervention - Dementia, Alzheimer Disease | Phase 3 | Completed | University of Pennsylvania | 421 | 2016-05-01 | 2024-07-26 |
| Symptomatic Treatment of Vascular Cognitive Impairment Galantamine, Methylphenidate, Placebo - Mild Cognitive Impairment (Vascular), Mild Cognitive Disorder (Vascular) | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 30 | 2014-02-01 | 2016-05-02 |
| Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Tianzhi granule and placebo identified to donepezil, Donepezil and placebo identified to Tianzhi granule, Placebo - Vascular Dementia | Phase 3 | Completed | Dongzhimen Hospital, Beijing | 543 | 2013-10-01 | 2020-01-07 |
| Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia DatSCAN - Lewy Body Dementia, Non-DLB Dementia | Phase 3 | Completed | GE Healthcare | 326 | 2003-11-01 | 2007-05-16 |
| Seroquel- Agitation Associated With Dementia Quetiapine Fumarate, Placebo - Alzheimer's Disease, Vascular Dementia | Phase 3 | Completed | AstraZeneca | 333 | 2002-09-01 | 2009-03-25 |
| Rivastigmine Capsules in Patients With Probable Vascular Dementia Rivastigmine - Vascular Dementia | Phase 3 | Completed | Novartis | 521 | 2002-02-01 | 2017-03-28 |
| Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Rivastigmine - Vascular Dementia | Phase 3 | Completed | Novartis Pharmaceuticals | 708 | 2001-08-01 | 2011-11-17 |
| A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia galantamine hydrobromide - Alzheimer Disease, Vascular Dementia | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 593 | 1998-12-01 | 2011-05-18 |
| A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Risperidone - Dementia, Alzheimer Disease | Phase 3 | Completed | Janssen-Cilag Pty Ltd | 344 | 1998-03-01 | 2010-11-19 |
Dementia, Vascular (13) · Dementia (5) · Alzheimer Disease (4) · Memory Disorders (3) · Cognitive Dysfunction (2) · Mixed Dementias (2) · Neurocognitive Disorders (2) · Chronobiology Disorders (1) · Disorders of Excessive Somnolence (1) · Frontotemporal Dementia (1) · Lewy Body Disease (1) · Psychomotor Agitation (1) · Sleep Disorders, Circadian Rhythm (1) · Sleep Initiation and Maintenance Disorders (1) · Sleep Wake Disorders (1)
Arterial Occlusive Diseases (13) · Arteriosclerosis (13) · Brain Diseases (13) · Cardiovascular Diseases (13) · Central Nervous System Diseases (13) · Cerebrovascular Disorders (13) · Intracranial Arterial Diseases (13) · Intracranial Arteriosclerosis (13) · Leukoencephalopathies (13) · Mental Disorders (13) · Nervous System Diseases (13) · Vascular Diseases (13) · Neurocognitive Disorders (11) · Dementia (8) · Neurodegenerative Diseases (5)
Galantamine (2) · Rivastigmine (2) · Donepezil (1) · Methylphenidate (1) · Quetiapine Fumarate (1) · Risperidone (1) · ioflupane (1) · sailuotong (1)
Amsterdam UMC, location VUmc (1) · AstraZeneca (1) · Capital Medical University (1) · Dongzhimen Hospital, Beijing (1) · GE Healthcare (1) · Janssen-Cilag Pty Ltd (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Materia Medica Holding (1) · Merz Pharmaceuticals GmbH (1) · Novartis (1) · Novartis Pharmaceuticals (1) · Shineway Pharmaceutical Co.,Ltd (1) · University of Pennsylvania (1)
China (3) · Russia (3) · Germany (2) · United States (2) · Austria (1) · Canada (1) · France (1) · Italy (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Jianping Jia, MD,PhD (1) · Jianping Jia, Professor (1) · Jinzhou Tian, MD,PhD (1) · Marc Pignot, PhD (1) · Nancy A. Hodgson (1) · Niels D Prins, MD, PhD (1) · Pavel Kamchatnov, professor (1)
PMID 11965273, PMID 12633121, PMID 18674411, PMID 24993764, PMID 29559423, PMID 31910895, PMID 32054507, PMID 33853394, PMID 34344312, PMID 39498781
R01NR015226 (1)